Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer.

Gynecologic oncology - 1 Apr 2026

Bashi Aya, Penvose Katherine N, Wright Jason D, Blank Stephanie V, Albright Benjamin B, Hazelton William D, Rossi Emma, Myers Evan R, Secord Angeles Alvarez, Havrilesky Laura J

Abstract excerpt

OBJECTIVE: We sought to identify efficient tumor molecular profiling strategies for patients with newly diagnosed stage III-IVA endometrial cancer. METHODS: We constructed a decision tree model to compare molecular profiling strategies. We considered testing options of mismatch repair (MMR), p53, and HER2 immunohistochemistry (IHC), and next generation sequencing (NGS, assessing for MMR protein, TP53 and POLE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Decision Trees

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Endometrial Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Neoplasm Staging

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42000378
DOI: 10.1016/j.ygyno.2026.02.009

Genes

POLE
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer.PMID 42000378Read ↗

Identification of molecular subtypes for endometrial carcinoma using a 46-gene next-generation sequencing panel: a retrospective study on a consecutive cohort.Semantic proximity Read ↗

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.Semantic proximity Read ↗

Analysis of Differences in the Classification of Endometrial Cancer Patients in PolandSemantic proximity Read ↗

Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.Semantic proximity Read ↗

[Comparative study of next generation sequencing and immunohistochemistry on molecular classification of endometrial carcinoma].Semantic proximity Read ↗

Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.Semantic proximity Read ↗

Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.Semantic proximity Read ↗

Molecular testing of endometrial carcinoma in real-world clinical practice.Semantic proximity Read ↗

Interpretation strategy of POLE, mismatch repair deficiency, and p53 in the multiple molecular classification of endometrial carcinoma and its clinical differences from single classification: a retrospective cohort study.Semantic proximity Read ↗

Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.Semantic proximity Read ↗

A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets.Semantic proximity Read ↗

Preoperative molecular classification of endometrial cancer: Validation through biopsy and matched hysterectomy specimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.